Nov 21, 2014

University of Pennsylvania Doses First Patient In Phase IIa Clinical Trial Using CardioCell’s Stem Cell Therapy To Treat Chronic Heart Failure (HF) Due To Non-Ischemic Cardiomyopathy

CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that creates allogeneic stem-cell therapies for cardiovascular indications, announces the treatment of its first patient in the University of Pennsylvania’s Phase IIa clinical trial for chronic heart failure (HF) of non-ischemic cardiomyopathy. READ FULL ARTICLE